Repligen Co. (NASDAQ:RGEN) Director Thomas F. Ryan, Jr. sold 4,696 shares of Repligen stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $36.16, for a total value of $169,807.36. Following the sale, the director now directly owns 9,700 shares in the company, valued at $350,752. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Repligen Co. (NASDAQ:RGEN) traded down $0.26 during midday trading on Monday, reaching $37.01. 232,450 shares of the company were exchanged, compared to its average volume of 269,316. Repligen Co. has a 52 week low of $29.56 and a 52 week high of $46.81. The stock has a market cap of $1,620.00, a price-to-earnings ratio of 74.16, a P/E/G ratio of 2.51 and a beta of 0.94. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.08 and a current ratio of 9.63.
Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. The business had revenue of $41.60 million during the quarter, compared to analyst estimates of $41.13 million. Repligen had a net margin of 20.08% and a return on equity of 7.08%. The company’s quarterly revenue was up 62.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.08 EPS. equities research analysts predict that Repligen Co. will post 0.7 earnings per share for the current year.
Several large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its stake in shares of Repligen by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,402 shares of the biotechnology company’s stock worth $1,095,000 after purchasing an additional 106 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of Repligen by 2.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 36,735 shares of the biotechnology company’s stock worth $1,522,000 after purchasing an additional 1,048 shares in the last quarter. First Manhattan Co. increased its stake in shares of Repligen by 16.7% in the 4th quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,500 shares in the last quarter. California Public Employees Retirement System increased its stake in shares of Repligen by 1.6% in the 3rd quarter. California Public Employees Retirement System now owns 122,548 shares of the biotechnology company’s stock worth $4,696,000 after purchasing an additional 1,948 shares in the last quarter. Finally, Nationwide Fund Advisors increased its stake in shares of Repligen by 2.4% in the 3rd quarter. Nationwide Fund Advisors now owns 84,480 shares of the biotechnology company’s stock worth $3,237,000 after purchasing an additional 1,979 shares in the last quarter. Hedge funds and other institutional investors own 87.60% of the company’s stock.
WARNING: “Repligen Co. (RGEN) Director Sells $169,807.36 in Stock” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/03/12/repligen-co-rgen-director-sells-169807-36-in-stock.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.